Background: The aim of this study was to assess acute and late morbidity measured by the physician and patient-reported outcomes (PROs) in high-risk prostate cancer (PC) patients receiving whole pelvic intensity-modulated radiotherapy (IMRT) in the setting of a national clinical trial. Material and methods: A total of 88 patients with adenocarcinoma of the prostate and high-risk parameters were enrolled from 2011 to 2013. All patients received 78 Gy in 39 fractions of IMRT delivering simultaneous 78 Gy to the prostate and 56 Gy to the seminal vesicles and lymph nodes. Physician-reported morbidity was assessed by CTCAE v.4.0. PROs were registered for gastro-intestinal (GI) by the RT-ARD score, genito-urinary (GU) by DAN-PSS, sexual and hormonal by EPIC-26, and quality of life (QoL) by EORTC QLQ-C30. Results: Median follow-up (FU) time was 4.6 years. No persistent late CTCAE grade 3+ morbidity was observed. Prevalence of CTCAE grade 2+ GI morbidities varied from 0 to 6% at baseline throughout FU time, except for diarrhea, which was reported in 19% of the patients post-RT. PROs revealed increased GI morbidity (≥1 monthly episode) for "rectal urgency", "use of pads", "incomplete evacuation", "mucus in stool" and "bowel function impact on QoL" all remained significantly different (p <.05) at 60 months compared to baseline. CTCAE grade 2+ GU and sexual morbidity were unchanged. GU PROs on obstructive and irritative GU items (≥daily episode) increased during RT and normalized at 24 months. No clinically significant differences were found in sexual, hormonal, and QoL scores compared to baseline. Conclusions: Whole pelvic RT resulted in a mild to the moderate burden of late GI morbidities demonstrated by a relatively high prevalence of PROs. Whereas, physician-assessed morbidity revealed a low prevalence of late GI morbidity scores. This emphasizes the importance of using both PROs and physician-reported scoring scales when reporting late morbidity in clinical trials.
|Number of pages||6|
|Publication status||Published - 2022|
|Event||BIGART 2021: Biology-Guided Adaptive Radiotherapy - Virtual|
Duration: 5 Oct 2021 → 6 Oct 2021
Conference number: 20
|Period||05/10/2021 → 06/10/2021|
Bibliographical notePublisher Copyright:
© 2021 Acta Oncologica Foundation.
- patient-reported outcomes
- Prostate cancer
- quality of life
FingerprintDive into the research topics of 'A phase I/II study of acute and late physician assessed and patient-reported morbidity following whole pelvic radiation in high-risk prostate cancer patients'. Together they form a unique fingerprint.
A phase I/II study of acute and late physician assessed and patient-reported morbidity following whole pelvic radiation in high-risk prostate cancer patients
Petersen, S. E. (Creator), Thorsen, L. B. (Creator), Hansen, S. (Creator), Petersen, P. M. (Creator), Lindberg, H. (Creator), Kempel, M. M. (Creator), Petersen, J. B. (Creator), Muren, L. P. (Creator), Høyer, M. (Creator) & Bentzen, L. (Creator), Taylor & Francis, 2021
DOI: 10.6084/m9.figshare.16646013.v1, https://tandf.figshare.com/articles/dataset/A_phase_I_II_study_of_acute_and_late_physician_assessed_and_patient-reported_morbidity_following_whole_pelvic_radiation_in_high-risk_prostate_cancer_patients/16646013/1
Dataset: Supplementary material